search
Back to results

Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL)

Primary Purpose

Lymphoma, T-Cell, Cutaneous

Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
ONTAK (denileukin difitox, DAB389IL-2)
Sponsored by
Eisai Inc.
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Lymphoma, T-Cell, Cutaneous focused on measuring Cutaneous, T-cell lymphoma, ONTAK, CD25

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Persistent or recurrent cutaneous T-cell lymphoma (CTCL) Stage IB-IVA as defined by TNM staging. Pathologic proven diagnosis (cytologically confirmed) of CTCL documented in patient history. Preserved organ function: Creatinine and/or Liver Function levels <1.5 times institutional upper limits of normal (ULN). Adequate liver function as indicated by bilirubin < or equal to 1.5 times ULN, ALT < or equal to 2 times ULN, AST < or equal to 2 times ULN. Albumin >3.0 g/dL Adequate renal function as indicated by SCr < or equal to 2.5 mg/dl. ECOG performance status between 0-2. Women of childbearing potential should be screened for pregnancy prior to treatment and utilize effective contraceptive methods (e.g. barrier) during treatment period. Patients over the age of 18 who are willing and able to provide Informed Consent. Exclusion Criteria: Pathology consistent with peripheral T-cell lymphoma. Stage IVB (visceral involvement with CTCL, other than lymph node involvement). History of Human Immunodeficiency Virus (HIV), Hepatitis B or Hepatitis C infection. Patients who are pregnant or breast feeding. Allergy to or have history of allergy to diphtheria toxin or IL-2. Previous ONTAK® usage. Unstable cardiovascular disease. Patients who have received systemic or topical antineoplastic therapy or investigational medications within past 14 days. Exception: Clear evidence of disease progression requiring immediate intervention and in the absence of ongoing toxicity from prior therapy. Ongoing deep vein thrombosis or a diagnosis of deep vein thrombosis less than 3 months prior to protocol enrollment.

Sites / Locations

  • City of Hope National Medical Center
  • Yale University School of Medicine
  • The University of Iowa
  • New England Medical Center
  • University Hospitals of Cleveland
  • Ohio State University
  • University of Pittsburgh
  • Vanderbilt University
  • The University of Texas MD Anderson Cancer Center

Outcomes

Primary Outcome Measures

To estimate response rates (CR + CCR + PR) according to CD25 status (CD25 positive and negative) after 4 cycles of ONTAK.

Secondary Outcome Measures

Physician's Global Assessment (PGA)
Time to Event Variables - Time to response, remission, treatment failure
Response based on the CD25 status
Response based on patient demographics: stage of disease, age, sex, performance status, total dose
Number of cycles completed
6. Assess safety and tolerability of ONTAK

Full Information

First Posted
September 13, 2005
Last Updated
February 29, 2008
Sponsor
Eisai Inc.
Collaborators
Tufts Medical Center, National Cancer Institute (NCI), Ligand Pharmaceuticals
search

1. Study Identification

Unique Protocol Identification Number
NCT00211198
Brief Title
Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL)
Official Title
Open Label Study of ONTAK® (Denileukin Diftitox, DAB389IL-2) to Estimate Response in Cutaneous T-Cell Lymphoma (CTCL) According to CD25 Status
Study Type
Interventional

2. Study Status

Record Verification Date
February 2008
Overall Recruitment Status
Completed
Study Start Date
May 2001 (undefined)
Primary Completion Date
January 2005 (Actual)
Study Completion Date
January 2006 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Eisai Inc.
Collaborators
Tufts Medical Center, National Cancer Institute (NCI), Ligand Pharmaceuticals

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this research study is to evaluate how effective ONTAK is in the treatment of cutaneous T-cell Lymphoma (CTCL) and determine whether the presence of a type of protein called CD25 on the cancer cells makes a difference in how the body responds to the treatment. The hypothesis is that there is no difference in response rate for patients whose tumor cells are CD25 positive or negative.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Lymphoma, T-Cell, Cutaneous
Keywords
Cutaneous, T-cell lymphoma, ONTAK, CD25

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
60 (false)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
ONTAK (denileukin difitox, DAB389IL-2)
Primary Outcome Measure Information:
Title
To estimate response rates (CR + CCR + PR) according to CD25 status (CD25 positive and negative) after 4 cycles of ONTAK.
Secondary Outcome Measure Information:
Title
Physician's Global Assessment (PGA)
Title
Time to Event Variables - Time to response, remission, treatment failure
Title
Response based on the CD25 status
Title
Response based on patient demographics: stage of disease, age, sex, performance status, total dose
Title
Number of cycles completed
Title
6. Assess safety and tolerability of ONTAK

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Persistent or recurrent cutaneous T-cell lymphoma (CTCL) Stage IB-IVA as defined by TNM staging. Pathologic proven diagnosis (cytologically confirmed) of CTCL documented in patient history. Preserved organ function: Creatinine and/or Liver Function levels <1.5 times institutional upper limits of normal (ULN). Adequate liver function as indicated by bilirubin < or equal to 1.5 times ULN, ALT < or equal to 2 times ULN, AST < or equal to 2 times ULN. Albumin >3.0 g/dL Adequate renal function as indicated by SCr < or equal to 2.5 mg/dl. ECOG performance status between 0-2. Women of childbearing potential should be screened for pregnancy prior to treatment and utilize effective contraceptive methods (e.g. barrier) during treatment period. Patients over the age of 18 who are willing and able to provide Informed Consent. Exclusion Criteria: Pathology consistent with peripheral T-cell lymphoma. Stage IVB (visceral involvement with CTCL, other than lymph node involvement). History of Human Immunodeficiency Virus (HIV), Hepatitis B or Hepatitis C infection. Patients who are pregnant or breast feeding. Allergy to or have history of allergy to diphtheria toxin or IL-2. Previous ONTAK® usage. Unstable cardiovascular disease. Patients who have received systemic or topical antineoplastic therapy or investigational medications within past 14 days. Exception: Clear evidence of disease progression requiring immediate intervention and in the absence of ongoing toxicity from prior therapy. Ongoing deep vein thrombosis or a diagnosis of deep vein thrombosis less than 3 months prior to protocol enrollment.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Francine Foss, M.D.
Organizational Affiliation
Yale University
Official's Role
Study Chair
Facility Information:
Facility Name
City of Hope National Medical Center
City
Duarte
State/Province
California
ZIP/Postal Code
91010
Country
United States
Facility Name
Yale University School of Medicine
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06520
Country
United States
Facility Name
The University of Iowa
City
Iowa City
State/Province
Iowa
ZIP/Postal Code
52242
Country
United States
Facility Name
New England Medical Center
City
Boston
State/Province
Massachusetts
Country
United States
Facility Name
University Hospitals of Cleveland
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44106
Country
United States
Facility Name
Ohio State University
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43210
Country
United States
Facility Name
University of Pittsburgh
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15213
Country
United States
Facility Name
Vanderbilt University
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37232
Country
United States
Facility Name
The University of Texas MD Anderson Cancer Center
City
Houston
State/Province
Texas
ZIP/Postal Code
77030-4009
Country
United States

12. IPD Sharing Statement

Citations:
Citation
Francine Foss, Madeleine Duvic, Larisa Geskin, Joseph Anderson, Pierluigi Porcu, Raymond J. Hohl, Maureen Cooper, Jasmine M. Zain, John Zic, Patrica Hibberd, and Mark Acosta Efficacy and Safety of Denileukin Diftitox (Ontak®) in the Treatment of Cutaneous T-Cell Lymphoma (CTCL) According to CD25 Status. Blood (ASH Annual Meeting Abstracts), Nov 2006; 108: 2712.
Results Reference
background

Learn more about this trial

Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL)

We'll reach out to this number within 24 hrs